News

The results showed that a single dose of REMD-477 substantially reduced daily insulin requirements and glucose levels without increasing hypoglycemia (low blood glucose levels) in patients. The randomized,

Under the agreement, TeneoBio will leverage Selexis’ proprietary SUREtechnology Platform to develop and optimize the cellular expression of multi-specific UniAbs that were discovered using TeneoBio’s proprietary sequence-based TeneoSeek discovery engine

Under the agreement, Numerate will drive discovery programs aimed at identifying clinical candidates for use in Takeda’s core therapeutic areas: oncology, gastroenterology, and central nervous system disorders. The

The company plans to discontinue the HCV candidate development, after the completion of the one remaining clinical study that is expected in July this year. Regulus has decided to terminate

The removal was sought after concerns that the risks associated with consuming the drug outweighed its benefits, stated the FDA. In fact, it marks the first time that the

The SAPHIR study is the first clinical trial to investigate the Glutaminylcyclase (QC) inhibitor PQ912 in patients with early AD over a treatment period of 12 weeks. The

In the studies, both doses of ertugliflozin tested (5 mg and 15 mg daily) achieved statistically significant reductions in A1C, a measure of average blood glucose over a

J&J signed an agreement in January this year to acquire Actelion, which develops and commercializes new drugs for diseases with significant unmet medical need. With the EC approval, the

Panobinostat will be developed by Midatech for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG) as a continuation of its existing MTX110 program, and potentially for Glioblastoma (GBM).